Insilico Medicine(“Insilico”), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced that the company has achieved a groundbreaking collaboration with Inimmune, which will utilize Chemistry42, Insilico’s proprietary generative artificial intelligence (AI) technology to accelerate the discovery and development of next-generation immunotherapeutics.
How the price of Lilly’s weight management drug could fuel its rivalry with Novo Nordisk
Eli Lilly’s highly anticipated weight loss rival Zepbound is set to hit shelves this year at a steep discount to Novo Nordisk’s Wegovy and with
November 10, 2023